A summary of economic evaluations published in the field of rheumatology and related disciplines

Arthritis and Rheumatism

Volumn 40, Issue 9, 1997, Pages 1587-1593

  Ferraz, Marcos Bosi ^a   Maetzel, Andreas ^b   Bombardier, Claire ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYLOSING SPONDYLITIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH PROGRAM; MEDICAL LITERATURE; OSTEOARTHRITIS; OSTEOPOROSIS; PRIORITY JOURNAL; PUBLICATION; RHEUMATOID ARTHRITIS;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; MEDLINE; QUALITY OF HEALTH CARE; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 0030824211     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400907     Document Type: Article

References (74)

1. Russell LB: Balancing cost and quality: methods of evaluation. Bull N Y Acad Med 62:55-60, 1986
2. Weinstein MC: Economic assessments of medical practices and technologies. Med Decis Making 1:309-330, 1981
3. Weinstein MC, Stason WB: Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716-721, 1977
4. Weinstein MC: Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care 6:93-103, 1990
5. Drummond MF: Allocating resources. Int J Technol Assess Health Care 6:77-92, 1990
6. Eisenberg JM: Clinical economics: a guide to the economic-analysis of clinical practices. JAMA 262:2879-2886, 1989
7. Drummond M, Stoddart G, Labelle R, Cushman R: Health economics: an introduction for clinicians. Ann Intern Med 107: 88-92, 1987
8. Langley PC: Outcomes research and modeling therapeutic interventions for economic evaluations. Clin Ther 16:538-552, 1994
9. Langley PC: Therapy evaluation, patient distribution, and cost-outcomes ratios. Clin Ther 17:341-347, 1995
10. Freund DA, Dittus RS: Principles for pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1:20-32, 1992
11. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
12. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, Schwartz JS: Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 324:1362-1365, 1991
13. Drummond M, Brandt A, Luce B, Rovira J: Standardizing methodologies for economic evaluation in health care: practice, problems, and potential. Int J Technol Assess Health Care 9:26-36, 1993
14. Canadian Coordinating Office for Health Technology Assessment: Guidelines for Economic Evaluation of Pharmaceuticals: Canada. First edition. Ottawa, CCOHTA, 1994
15. Ontario Ministry of Health: Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto, Queen's Printer for Ontario, 1994
16. Commonwealth Department of Human Services and Health: Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Submissions Involving Economic Analyses. Canberra, Australian Government Publishing Service, 1995
17. Evans RG: Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med 123:59-60, 1995
18. Task Force on Principles for Economic Analysis of Health Care Technology: Economic analysis of health care technology: a report on principles. Ann Intern Med 123:61-70, 1995
19. Mason J, Drummond M: Reporting guidelines for economic studies. Health Econ 4:85-94, 1995
20. Kassirer JP, Angell M: The journal's policy on cost-effectiveness analyses. N Engl J Med 331:669-670, 1994
21. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC, for the Panel on Cost-Effectiveness in Health and Medicine: The role of cost-effectiveness analysis in health and medicine. JAMA 276:1172-1177, 1996
22. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine: Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1253-1258, 1996
23. Siegel JE, Weinstein MC, Russell LB, Gold MR, for the Panel on Cost-Effectiveness in Health and Medicine: Recommendations for reporting cost-effectiveness analyses. JAMA 276:1339-1341, 1996
24. Fryback DG: QALYs, HYEs, and the loss of innocence. Med Decis Making 13:271-272, 1993
25. Richardson J: Cost utility analysis: what should be measured? Soc Sci Med 39:7-21, 1994
26. Cairns JA: Valuing future benefits. Health Econ 3:221-229, 1994
27. Krahn M, Gafni A: Discounting in the economic evaluation of health care interventions. Med Care 31:403-418, 1993
28. Redelmeier DA, Heller DN: Time preference in medical decision making and cost-effectiveness analysis. Med Decis Making 13:212-217, 1993
29. Keeler EB, Cretin S: Discounting of life-saving and other nonmonetary effects. Manage Science 29:300-306, 1983
30. Van Hout BA, Al MJ, Gordon GS, Rutten FF: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3:309-319, 1994
31. O'Brien BJ, Drummond MF, Labelle RJ, Willan A: In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 32:150-163, 1994
32. Drummond M, O'Brien B: Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes. Health Econ 2:2115-212, 1993
33. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM: Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly? Ann Intern Med 116:238-244, 1992
34. Drummond MF, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. Oxford, Oxford University Press, 1987
35. Jönsson B, Haglund U: Cost-effectiveness of misoprostol in Sweden. Int Technol Assess Health Care 8:234-244, 1992
36. De Pouvourville G, Bader JP: Cost-effectiveness of preventive treatment with misoprostol in non-steroidal anti-inflammatory agents related gastric ulcers. Gastroenterol Clin Biol 15:399-404, 1991
37. Knill-Jones R, Drummond M, Kohli H, Davies L: Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 66:639-646, 1990
38. Gabriel SE, Campion ME, O'Fallon WM: A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 37:333-341, 1994
39. Hillman AL, Bloom BS: Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 149:2061-2065, 1989
40. Edelson JT, Tosteson AN, Sax P: Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 264:41-47, 1990
41. Carrin GJ, Torfs KE: Economic evaluation of prophylactic treatment with misoprostol in osteoarthritic patients treated with NSAIDs: the case of Belgium. Rev Epidemiol Sante Publique 38:187-199, 1990
42. Bentkover JD, Baker AM, Kaplan H: Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. PharmacoEconomics 5:335-342, 1994
43. Gabriel SE, Jaakkimainen RL, Bombardier C: The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 36:447-459, 1993
44. Cheung AP, Wren BG: A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 156:312-316, 1992
45. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M: HRT: an analysis of benefits, risks and costs. Br Med Bull 48:368-400, 1992
46. Torgerson DJ, Reid DM: Osteoporosis prevention through screening: will it be cost effective? Baillieres Clin Rheumatol 7:603 622, 1993
47. Garton MJ, Torgerson DJ, Donaldson C, Russell IT, Reid DM: Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study. BMJ 305:82-84, 1992
48. Geelhoed E, Harris A, Prince R: Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 18:153-160, 1994
49. Tosteson AN, Rosenthal DI, Melton LJ, Weinstein MC: Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113:594-603, 1990
50. Weinstein MC, Schiff I: Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 38:445-455, 1983
51. Weinstein MC, Tosteson ANA: Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 592:162-172, 1990
52. Chang RW, Falconer J, Stulberg SD, Arnold WJ, Manheim LM, Dyer AR: A randomized, controlled trial of arthroscopic surgery versus closed-needle joint lavage for patients with osteoarthritis of the knee. Arthritis Rheum 36:289-296, 1993
53. McInnes J, Larson MG, Daltroy LH, Brown T, Fossel AH, Eaton HM, Shulman-Kirwan B, Steindorf S, Poss R, Liang MH: A controlled evaluation of continuous passive motion in patients undergoing total knee arthroplasty. JAMA 268:1423-1428, 1992
54. Rorabeck CH, Bourne RB, Laupacis A, Feeny D, Wong C, Tugwell P, Leslie K, Bullas R: A double-blind study of 250 cases comparing cemented with cementless total hip arthroplasty: cost-effectiveness and its impact on health-related quality of life. Clin Orthop 298:156-164, 1994
55. Weinberger M, Tierney WM, Cowper PA, Katz BP, Booher PA: Cost-effectiveness of increased telephone contact for patients with osteoarthritis: a randomized, controlled trial. Arthritis Rheum 36:243-246, 1993
56. Liang MH, Cullen KE, Larson MG, Thompson MS, Schwartz JA, Fossel AH, Roberts WN, Sledge CB: Cost-effectiveness of total joint arthroplasty in osteoarthritis. Arthritis Rheum 29:937-943, 1986
57. Lambert CM, Hurst NP, Lochhead A, McGregor K, Hunter M, Forbes J: A pilot study of the economic cost and clinical outcome of day patient vs inpatient management of active rheumatoid arthritis. Br J Rheumatol 33:383-338, 1994
58. Anderson RB, Needleman RD, Gatter RA, Andrews RP, Scarola JA: Patient outcome following inpatient vs outpatient treatment of rheumatoid arthritis. J Rheumatol 15:556-560, 1988
59. Helewa A, Bombardier C, Goldsmith CH, Menchions B, Smythe HA: Cost-effectiveness of inpatient and intensive outpatient treatment of rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 32:1505-1514, 1989
60. Thompson MS, Read JL, Hutchings HC, Paterson M, Harris ED Jr: The cost effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 15:35-42, 1988
61. Brown KC, Sirles AT, Hilyer JC, Thomas MJ: Cost-effectiveness of a back school intervention for municipal employees. Spine 17:1224-1228, 1992
62. Versloot JM, Rozeman A, van Son AM, van Akkerveeken PF: The cost-effectiveness of a back school program in industry: a longitudinal controlled field study. Spine 17:22-27, 1992
63. Mitchell LV, Lawler FH, Bowen D, Mote W, Asundi P, Purswell J: Effectiveness and cost-effectiveness of employer-issued back belts in areas of high risk for back injury. J Occup Med 36:90-94, 1994
64. Coulehan JL, Baacke G, Welty TK, Goldtooth NL: Cost-benefit of a streptococcal surveillance program among Navajo Indians. Public Health Rep 97:73-77, 1982
65. Tompkins RK, Burnes DC, Cable WE: An analysis of the cost-effectiveness of pharyngitis management and acute rheumatic fever prevention. Ann Intern Med 86:481-492, 1977
66. Lorig KR, Mazonson PD, Holman HR: Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum 36:439-446, 1993
67. McInnes PM, Schuttinga J, Sanslone WR, Stark SP, Klippel JH: The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide. Arthritis Rheum 37:1000-1006, 1994
68. Lightfoot RW Jr, Luft BJ, Rahn DW, Steere AC, Sigal LH, Zoschke DC, Gardner P, Britton MC, Kaufman RL: Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: a cost-effectiveness analysis. Ann Intern Med 119:503-509, 1993
69. Bakker C, Hidding A, van der Linden S, van Doorslaer E: Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis: a randomized controlled trial. J Rheumatol 21:264-268, 1994
70. Tsevat J, Durand-Zaleski I, Pauker SG: Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints. Am J Public Health 79:739-743, 1989
71. Stucki G, Johannesson M, Liang MH: Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med 154:2020-2025, 1994
72. Jefferson T, Mugford M, Gray A, Demicheli V: An exercise on the feasibility of carrying out secondary economic analyses. Health Econ 5:155-165, 1996
73. Dolan P, Gudex C, Kind P, Williams A: Valuing health states: a comparison of methods. J Health Econ 15:209-231, 1996
74. Sheldon TA: Problems of using modelling in the economic evaluation of health care. Health Econ 5:1-11, 1996